BIKTARVY Drug Patent Profile

« Back to Dashboard

Which patents cover Biktarvy, and what generic alternatives are available?

Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in BIKTARVY is bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Biktarvy

Biktarvy was eligible for patent challenges on February 7, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 8, 2036. This may change due to patent challenges or generic licensing.

There have been twenty-two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BIKTARVY

US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	44
Drug Prices:	Drug price information for BIKTARVY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BIKTARVY
What excipients (inactive ingredients) are in BIKTARVY?	BIKTARVY excipients list
DailyMed Link:	BIKTARVY at DailyMed

See drug prices for BIKTARVY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BIKTARVY

NDA:

210251

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BIKTARVY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Trutag Technologies	NA
Gilead Sciences	NA
Brigham and Women's Hospital	NA

See all BIKTARVY clinical trials

Pharmacology for BIKTARVY

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for BIKTARVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	30 mg/120 mg/ 15 mg	210251	1	2023-09-28
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	50 mg/200 mg/ 25 mg	210251	3	2022-02-07

US Patents and Regulatory Information for BIKTARVY

BIKTARVY is protected by nine US patents and six FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No					Y
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No			Y	Y

Expired US Patents for BIKTARVY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018

International Patents for BIKTARVY

When does loss-of-exclusivity occur for BIKTARVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Cuba

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

New Zealand

Peru

Philippines

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BIKTARVY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	100903
Australia	2015276860
Australia	2018203175
Brazil	112016029605
Brazil	122021025861

Supplementary Protection Certificates for BIKTARVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	2016/014	Ireland		PRODUCT NAME: TENOFOVIR ALAFENAMIDE OR A SALT OR SOLVATE THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061/001-EU/1/15/1061/002 20151119
0513200	91073	Luxembourg		91073, EXPIRES: 20160131
0513200	300148	Netherlands		300148, 20110131, EXPIRES: 20160130
0513200	SPC/GB04/016	United Kingdom		PRODUCT NAME: EMTRICITABINE OR SALTS AND ESTERS THEREOF; REGISTERED: UK EU/1/03/261/001 20031024; UK EU/1/03/261/002 20031024; UK EU/1/03/261/003 20031024
0513200	SZ 7/2004	Austria

Biktarvy Market Dynamics, Patent Exclusivity, Competition, and Financial Trajectory

Last updated: September 29, 2026

Biktarvy generated approximately $13.4 billion in global product sales in 2024, making it Gilead Sciences’ largest commercial product and one of the leading HIV medicines worldwide. Sales rose from about $1.2 billion in 2018 to more than $13 billion in 2024, driven by rapid adoption of single-tablet therapy, switching from older regimens, strong U.S. formulary positioning, and continued international expansion.[1-7]

The principal commercial risk is not near-term clinical substitution. It is eventual generic erosion after the expiration or settlement of patents covering bictegravir, the bictegravir/emtricitabine/tenofovir alafenamide combination, and Biktarvy formulations. The effective U.S. generic-entry date is likely to depend on Orange Book patents, Paragraph IV litigation, and any settlement terms rather than on the earliest compound-patent expiration alone.

What is Biktarvy and how does it generate revenue?

Biktarvy is a fixed-dose, once-daily, single-tablet HIV-1 treatment containing:

Component	Drug class	Function
Bictegravir	Integrase strand transfer inhibitor	Blocks HIV integrase
Emtricitabine	Nucleoside reverse transcriptase inhibitor	Inhibits reverse transcription
Tenofovir alafenamide	Nucleotide reverse transcriptase inhibitor	Delivers tenofovir with lower systemic exposure than TDF

Gilead markets Biktarvy as a complete regimen for adults and pediatric patients weighing at least 14 kilograms with HIV-1 who have no current or prior evidence of resistance to the product’s components.[8]

Its commercial model is based on chronic, lifelong treatment. Patient retention produces recurring revenue, while new starts and switches from older regimens expand the treated base. The product also benefits from the simplicity of a one-pill regimen, which reduces pill burden and supports adherence.

Biktarvy is not a biologic. It is a chemically synthesized small-molecule combination product. Biosimilar competition therefore does not apply. Future competition will come from conventional generic or authorized-generic versions, alternative branded HIV regimens, and long-acting injectable products.

How has Biktarvy’s financial trajectory developed?

Biktarvy sales have expanded every year since launch.

Fiscal year	Global Biktarvy product sales	Approximate annual growth
2018	$1.2 billion	Initial launch year
2019	$5.1 billion	329%
2020	$7.3 billion	43%
2021	$8.6 billion	19%
2022	$10.4 billion	21%
2023	$11.8 billion	14%
2024	$13.4 billion	13%

Sources: Gilead annual reports and quarterly earnings disclosures.[1-7]

Biktarvy represented roughly 45% to 47% of Gilead’s total product sales in 2023 and 2024, depending on the company’s reported total-sales denominator. That concentration creates material earnings exposure. Continued Biktarvy growth supports Gilead’s HIV franchise, but a future U.S. generic launch would affect revenue, gross margin, and the valuation of the company’s HIV portfolio.

The growth rate has moderated from the launch period, but the product remains in a high-value expansion phase. The commercial trajectory is supported by:

• Switching from older integrase-based and tenofovir-containing regimens.
• Continued diagnosis and treatment of people living with HIV.
• High persistence once patients begin therapy.
• Broad use across treatment-naive and treatment-experienced patients.
• International expansion and reimbursement access.
• A strong position in U.S. commercial and government channels.

What is the FDA and regulatory status of Biktarvy?

The FDA approved Biktarvy on April 5, 2018, as a complete regimen for HIV-1 infection in adults without a history of treatment failure or known resistance to bictegravir, emtricitabine, or tenofovir.[8]

The FDA later expanded the label to pediatric patients weighing at least 14 kilograms. Biktarvy is also used in patients with renal considerations, although the label contains restrictions for severe renal impairment and dialysis populations.[8]

Biktarvy is not approved to treat chronic hepatitis B infection as a standalone therapy. Because emtricitabine and tenofovir alafenamide are active against hepatitis B virus, discontinuation in a coinfected patient can cause hepatitis B exacerbation. The label requires appropriate monitoring and management.[8]

The product has no biosimilar pathway. Generic applicants would use an abbreviated new drug application, or ANDA, demonstrating pharmaceutical equivalence and bioequivalence to the reference-listed drug.

What patents protect Biktarvy?

Biktarvy is protected by several overlapping patent categories:

1. Bictegravir compound and chemical-family patents.
2. Fixed-dose combination patents.
3. Pharmaceutical composition and formulation patents.
4. Treatment-method patents.
5. Patent claims covering specific salts, crystalline forms, or manufacturing processes.

The most commercially important protection is the combination of compound and product patents. A generic applicant may challenge one or more patents through a Paragraph IV certification, but the generic cannot launch lawfully if an enforceable patent remains in force or if litigation results in a launch restriction.

Publicly associated Biktarvy and bictegravir patent families include the following U.S. patents:

Patent	General protection category	Commercial relevance
U.S. Patent No. 9,393,208	Bictegravir-related antiviral claims	Core active-ingredient protection
U.S. Patent No. 10,130,642	Bictegravir and related antiviral compositions	Core compound and composition protection
U.S. Patent No. 10,413,543	Bictegravir combination or pharmaceutical composition claims	Product-level protection
U.S. Patent No. 10,583,110	Combination and formulation-related claims	Extends product protection
U.S. Patent No. 10,857,205	Biktarvy-related composition or treatment claims	Later-layer protection
U.S. Patent No. 11,406,646	Later-filed treatment or composition claims	Potentially relevant to post-2030 protection

The exact enforceable scope depends on claim construction, terminal disclaimers, patent-term adjustment, patent-term extension, Orange Book listing status, and the facts of any ANDA litigation. The earliest compound-related rights do not necessarily determine the final generic-entry date.

Gilead’s HIV products often use layered patent protection rather than relying on one patent. That structure increases litigation complexity and can support a later negotiated launch date even if an early patent is vulnerable.

When does Biktarvy lose exclusivity?

Biktarvy’s regulatory exclusivity began with its 2018 FDA approval. New chemical entity exclusivity associated with bictegravir would have covered the initial five-year period, with pediatric exclusivity potentially adding six months to qualifying regulatory protections.[8,9]

Regulatory exclusivity is no longer the principal barrier. Patent rights are more important.

U.S. patent timing

The earliest relevant patent expirations are expected to occur before the latest formulation and combination patents. Public patent records indicate that some bictegravir-related rights may expire in the late 2020s or early 2030s, while later Biktarvy-related patents may extend into the mid-2030s.[9-11]

A practical U.S. launch analysis should distinguish among:

• Earliest invalidation or expiration date.
• Latest Orange Book-listed patent date.
• Patent-term adjustment.
• Pediatric exclusivity.
• The result of Paragraph IV litigation.
• Any negotiated generic-entry date.

The commercial base case is that Biktarvy remains substantially protected in the United States into the early 2030s, subject to litigation and settlement outcomes. Later patents could delay unrestricted competition beyond the first patent expiry if they survive challenge and cover the marketed product.

International timing

Patent terms and regulatory exclusivity differ by country. European and other developed markets generally provide a 20-year patent term from the relevant filing date, with supplementary protection certificates or equivalent extensions potentially affecting some products. Patent coverage in emerging markets is less uniform.

Generic entry may therefore occur in selected non-U.S. countries before the United States. Gilead’s international revenue exposure is meaningful, but U.S. pricing and volume make the U.S. market the most important determinant of global erosion.

What Paragraph IV challenges and litigation affect Biktarvy?

Generic manufacturers can submit ANDAs with Paragraph IV certifications asserting that Orange Book-listed patents are invalid, unenforceable, or not infringed. Gilead may then file patent-infringement litigation within 45 days, triggering an automatic FDA approval stay of up to 30 months under the Hatch-Waxman Act.[12]

Biktarvy is an attractive Paragraph IV target because:

• Annual sales exceed $13 billion.
• The product has high prescription volume.
• The regimen is relatively straightforward to copy.
• A successful challenge could create a large generic market.
• Multiple manufacturers could enter after the first launch.

Public docket and patent-record monitoring is required to identify the first ANDA applicants, the patents challenged, and any 180-day exclusivity claims. The presence of a Paragraph IV filing does not establish a launch date. Litigation settlements can authorize entry before the final patent expiration while preserving substantial branded revenue.

What settlement agreements could mean for generic entry?

A settlement could specify:

• An agreed generic launch date.
• A license to specified patents.
• Royalty obligations.
• Authorized-generic rights.
• Restrictions on manufacturing or distribution.
• Non-contest provisions.
• Supply or licensing arrangements.

For a product with Biktarvy’s revenue scale, a settlement that allows entry several years before the latest patent expiration could still be economically rational for both parties. Gilead would retain branded sales until the negotiated date, while the generic applicant would obtain a defined launch window and avoid litigation risk.

How strong is the Biktarvy patent estate?

Biktarvy has a strong commercial patent estate, but its strength is not uniform across every patent family.

Strengths

The estate benefits from:

• Multiple patent layers.
• A commercially important active ingredient.
• Fixed-dose combination claims.
• Formulation and treatment claims.
• High economic value that supports extensive litigation.
• A product that is difficult to substitute immediately for all patients.

Vulnerabilities

Potential weaknesses include:

• Earlier compound patents may face prior-art and obviousness challenges.
• Combination claims can be challenged on obviousness grounds.
• Formulation patents may cover narrower technical features.
• Some later patents may not block every possible generic design.
• A generic applicant can attempt a non-infringing formulation or seek a judgment on selected claims.

Patent strength should therefore be assessed claim by claim. The economic strength of Biktarvy is higher than the strength of any single patent because Gilead can rely on overlapping rights.

How does Biktarvy compare with competing HIV treatments?

Product	Company	Format	Main competitive position
Biktarvy	Gilead	Once-daily tablet	Broad single-tablet use and strong commercial uptake
Dovato	ViiV Healthcare	Once-daily two-drug tablet	Two-drug regimen with lower NRTI burden
Triumeq	ViiV Healthcare	Once-daily tablet	Established integrase-based regimen, now older
Juluca	ViiV Healthcare	Once-daily two-drug tablet	Switch option for virologically suppressed patients
Genvoya	Gilead	Once-daily tablet	Earlier TAF-based regimen
Odefsey	Gilead	Once-daily tablet	Smaller-tablet, lower-pill-burden option
Symtuza	Johnson & Johnson/Gilead-related commercial ecosystem	Once-daily tablet	Boosted protease-inhibitor regimen
Cabenuva	ViiV Healthcare	Long-acting injectable	Reduces daily oral dosing

Biktarvy’s main branded threat is Cabenuva, not a direct tablet equivalent. Long-acting injectable treatment can attract patients who prefer less frequent dosing, although administration logistics, clinic capacity, tolerability, and reimbursement affect adoption.

Dovato is the most relevant oral two-drug competitor. Its lower active-ingredient count may appeal to prescribers concerned about long-term exposure, but Biktarvy retains advantages in prescribing familiarity, treatment breadth, and commercial scale.

What generic launch scenarios exist for Biktarvy?

Scenario 1: No meaningful U.S. generic entry before the early 2030s

This is the most favorable scenario for Gilead. Biktarvy continues to grow internationally while U.S. sales mature. The company uses its HIV portfolio and newer products to offset eventual erosion.

Scenario 2: Settled entry before the latest patent expiry

A settlement permits one or more generic manufacturers to launch on an agreed date. Revenue declines gradually before the final patent expiry, but branded Biktarvy retains substantial share because of physician familiarity, payer contracts, and patient continuity.

Scenario 3: Early court victory for a generic challenger

A court invalidates or finds non-infringement of key patents. Multiple ANDA holders may launch, producing rapid price compression and high-volume substitution. This is the highest-risk outcome for Biktarvy revenue.

Scenario 4: Authorized generic or licensed competition

Gilead licenses a generic version or launches an authorized generic. This can preserve some economics and manage channel disruption, but it accelerates price competition and reduces the value captured by the branded product.

What is the commercial outlook for Biktarvy?

Biktarvy should remain a core Gilead revenue asset through the second half of the 2020s. Growth will likely slow as the treated population matures, competition increases, and the product reaches a larger share of the addressable single-tablet market.

The main operating variables are:

• New patient starts.
• Switching from older regimens.
• U.S. formulary access.
• International reimbursement.
• Use in adolescents and children.
• Price and gross-to-net pressure.
• Cabenuva adoption.
• Generic patent challenges.
• Gilead’s ability to shift patients toward other HIV products before erosion.

The product’s risk profile is asymmetric. Before generic entry, Biktarvy has recurring, high-margin revenue with strong market position. After generic entry, price erosion can be rapid because the active ingredients are chemically defined and the product is suitable for ANDA competition. The timing of that transition is more important than small changes in annual prescription growth.

Key Takeaways

• Biktarvy sales increased from approximately $1.2 billion in 2018 to $13.4 billion in 2024.
• The product is Gilead’s largest commercial medicine and represents roughly half of company product sales.
• FDA approval occurred in April 2018, with later pediatric expansion.
• Biktarvy faces generic, not biosimilar, competition.
• Its patent estate includes compound, combination, formulation, and treatment-method rights.
• U.S. generic entry is likely to depend on Paragraph IV litigation and settlement terms.
• The commercial base case supports substantial protection into the early 2030s, although individual patent dates differ.
• Cabenuva and Dovato are the principal branded competitive risks.
• Generic entry could produce rapid U.S. price erosion because the product is a chronic small-molecule regimen.

FAQs About Biktarvy Market and Patent Risk

Is Biktarvy still growing?

Yes. Global product sales reached approximately $13.4 billion in 2024, up from about $11.8 billion in 2023.[1,2]

Does Biktarvy have biosimilar competition?

No. Biktarvy is a small-molecule combination product. Competition would come through ANDA-based generic approval rather than biosimilar approval.

Is Biktarvy protected by a composition patent?

Yes. The patent estate includes composition, bictegravir, combination, formulation, and treatment-related claims. The relevant protection varies by patent family and jurisdiction.

Can generic Biktarvy launch before every patent expires?

Potentially. A generic could launch after winning Paragraph IV litigation, through a license, or under a settlement that authorizes entry before the latest patent expiration.

What is the biggest long-term risk to Biktarvy revenue?

The main risk is U.S. generic entry that triggers rapid price and volume erosion. Branded competition is important, but it is less likely to cause the same magnitude of revenue loss as multiple generic launches.

References

1. Gilead Sciences, Inc. (2019). 2018 annual report.
2. Gilead Sciences, Inc. (2020). 2019 annual report.
3. Gilead Sciences, Inc. (2021). 2020 annual report.
4. Gilead Sciences, Inc. (2022). 2021 annual report.
5. Gilead Sciences, Inc. (2023). 2022 annual report.
6. Gilead Sciences, Inc. (2024). 2023 annual report.
7. Gilead Sciences, Inc. (2025). 2024 annual report.
8. U.S. Food and Drug Administration. (2024). Biktarvy prescribing information.
9. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
10. United States Patent and Trademark Office. (2024). Patent Center and patent term information for U.S. patents associated with bictegravir and Biktarvy.
11. Google Patents. (2024). U.S. patent records for bictegravir and Biktarvy-related patent families.
12. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355.

DrugChatter Q&A for BIKTARVY

Biktarvy patient assistance program?
How much does biktarvy cost in ghana 2021?
Does biktarvy expire?
How long has biktarvy been around?
Biktarvy release date?